Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The tandem CD33-CLL1 CAR-T as an approach to treat acute myeloid leukemia.

18 Jul 2025

Abstract excerpt

BACKGROUND: Acute myeloid leukemia (AML) is characterized by high heterogeneity, poor long-term survival, and a propensity for relapse. Exceptional efficacy in treating recurrent or refractory B-lymphoid malignancies has been demonstrated by Chimeric antigen receptor T cells (CAR-T cells). Given the therapeutic potential of targeting both CD33 and C-type lectin-like molecule-1 (CLL1) in AML, the development of a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to CAR-T cell therapy research
Share to Cutaneous lymphoproliferative disorders research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39133622
DOI: 10.2450/bloodtransfus.786

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The tandem CD33-CLL1 CAR-T as an approach to treat acute myeloid leukemia.PMID 39133622Read ↗

Differential TIM-3 glycosylation enables specific dual targeting CAR-T therapy in acute myeloid leukemiaSemantic proximity Read ↗

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.Semantic proximity Read ↗

In-depth comparative characterization identifies scalable CD123-CAR-NK cells as promising strategy to combat AMLSemantic proximity Read ↗

Modified CD15/CD16-CLL1 inhibitory CAR-T cells for mitigating granulocytopenia toxicities in the treatment of acute myeloid leukemiaSemantic proximity Read ↗

Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in Acute Myeloid LeukemiaSemantic proximity Read ↗

MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem CellsSemantic proximity Read ↗

Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon SystemSemantic proximity Read ↗

Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.Semantic proximity Read ↗

Rational Combinatorial Targeting by Adapter CAR T Cells (AdCAR-T) Prevents Antigen Escape in Acute Myeloid Leukemia (AML)Semantic proximity Read ↗

IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cellsSemantic proximity Read ↗

Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.Semantic proximity Read ↗

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.